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The proper development and coordination of the hypothalamic-pituitary-gonadal (HPG) axis are essential for normal reproduc-
tive competence. The key factor that regulates the function of the HPG axis is gonadotrophin-releasing hormone (GnRH). Timely 
release of GnRH is critical for the onset of puberty and subsequent sexual maturation. Misregulation in this system can result in 
delayed or absent puberty and infertility. Congenital hypogonadotropic hypogonadism (CHH) and Kallmann syndrome (KS) are 
genetic disorders that are rooted in a GnRH deficiency but often accompanied by a variety of non-reproductive phenotypes such 
as the loss of the sense of smell and defects of the skeleton, eye, ear, kidney, and heart. Recent progress in DNA sequencing tech-
nology has produced a wealth of information regarding the genetic makeup of CHH and KS patients and revealed the resilient yet 
complex nature of the human reproductive neuroendocrine system. Further research on the molecular basis of the disease and the 
diverse signal pathways involved will aid in improving the diagnosis, treatment, and management of CHH and KS patients as 
well as in developing more precise genetic screening and counseling regime.
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INTRODUCTION 
Idiopathic congenital hypogonadotropic hypogonadism (CHH) 
is a rare reproductive disorder that is primarily caused by a go-
nadotrophin-releasing hormone (GnRH) deficiency but with 
significant genetic heterogeneity. Clinically, this disorder is 
characterized by abnormally low plasma levels of luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH) in con-
junction with low or undetectable concentrations of circulating 
sex steroids. In approximately 50% of cases, CHH patients also 
suffer from a reduced or deficient sense of smell (hyposmia or 
anosmia, respectively), which is then termed as Kallmann syn-
drome (KS) [1,2]. 
 KS was first recognized in 1856 by Maestre de San Juan [1] 
who observed patients with defective olfactory structures and a 
microphallus. A few years later, Kallmann et al. [2] identified 
the hereditary nature of this condition. In the 1950s, De Morsi-
er and Gauthier [3] further described the partial or complete 
absence of the olfactory bulb (OB) and its axons in multiple 
hypogonadal males. Since then, a variety of non-reproductive 
dysfunctions and developmental anomalies have been observed 
in association with hypogonadism. This review aimed to pro-
vide a brief overview of the genetics, molecular pathogenesis, 
diagnosis, and treatment of CHH and KS, with a particular fo-
cus on recent progress in the field.
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THE HYPOTHALAMIC-PITUITARY-
GONADAL AXIS 
Multiple developmental and neuroendocrine signaling path-
ways regulate the ontogeny and homeostasis of the GnRH neu-
rons including the production, secretion, and action of GnRH 
[4]. The development of the olfactory system and GnRH neu-
rons are intimately connected with each other and are often 
modulated by common cell surface receptors and chemoattrac-
tant or chemorepellent molecules. During early embryogenesis, 
GnRH neurons originate from the neural crest and ectodermal 
progenitors within the olfactory placode outside of the brain 
and then migrate in close association with the growing axons 
of olfactory receptor neurons and terminal nerves. After pene-
trating through the cribriform plate, the GnRH neurons arrive 
in the hypothalamus, where they detach from the olfactory axo-
nal guides, become non-motile, and then disperse further into 
the brain basal lamina before undergoing terminal differentia-
tion [5]. In mice, this migratory process begins at embryonic 
day E10.5 and is completed by E17.5 [6]. The timed and coor-
dinated expressions of various cell adhesion molecules, axonal 
guidance cues, and extracellular matrix proteins, along with 
different neurotransmitters, transcription factors, and growth 
factors that regulate the migration of GnRH neurons, have been 
documented [5]. 
 Within the hypothalamus, functional GnRH neurons extend 
their axonal processes to the medial eminence through which 
pulsatile GnRH is secreted into circulation via the hypophyseal 
portal system. GnRH binds to GnRH receptor 1 (GnRHR1) on 
gonadotroph cells in the anterior pituitary and stimulates the 
synthesis and secretion of LH and FSH. Subsequently, LH acts 
on the testes to stimulate testosterone production, and LH and 
FSH act on the ovaries to induce estrogen production which, in 
turn, leads to steroidogenesis and germ cell production [4]. 
GnRH is temporarily secreted at 3 to 6 months postnatally, 
which is more evident in boys than girls and is sometimes 
called “mini-puberty.” GnRH secretion then remains dormant 
until the onset of puberty, when its reactivation initiates sec-
ondary sexual maturation [4]. Therefore, the normal develop-
ment and properly coordinated actions of the hypothalamic-pi-
tuitary-gonadal (HPG) axis are essential for GnRH pulse gen-
eration and normal reproductive function (Fig. 1). 
 The examination of a 19-week-old human aborted fetus with 
X-linked KS revealed that the GnRH neurons were arrested in 
a tangle above the cribriform plate [7]. Because the initial dif-
ferentiation and migration of the GnRH precursor cells ap-
peared to be normal, it was speculated that the subsequent axo-
nal elongation, path-finding, and/or terminal differentiation 
Fig. 1. The hypothalamic-pituitary-gonadal (HPG) axis. During 
early brain development, gonadotrophin-releasing hormone 
(GnRH)-releasing neurons (green) migrate from the nasal region 
to the hypothalamus, where they permanently reside and differen-
tiate. Hypothalamic GnRH neurons secrete GnRH at the median 
eminence into the hypophyseal portal system and release pulsatile 
GnRH to the anterior pituitary. GnRH then binds to GnRH recep-
tor 1 on the gonadotrophs to stimulate these cells to produce lu-
teinizing hormone (LH) and follicle-stimulating hormone (FSH), 
which enter the systemic blood stream through the hypophyseal 
veins. LH and FSH act on the gonads (Sertoli and Leydig cells in 
testes and cumulus, mural and thecal cells in ovaries) to induce 
steroidogenesis and germ cell production which, in turn, main-
tains sexual competence. The release of kisspeptin from the hypo-
thalamic neurons located in the arcuate (ARC) and anteroventral 
periventricular nuclei within the preoptic area is critically impor-
tant for the re-initiation of pulsatile GnRH secretion at puberty. 
The developmental failure or misregulation of any one or combi-
nation of the genes involved in GnRH migration, secretion, and 
activity at any stage of development may result in congenital hy-
pogonadotropic hypogonadism and Kallmann syndrome. AVPV, 
anteroventral periventricular nucleus.
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processes might have been disrupted and prevented the GnRH 
neurons from reaching the forebrain [7]. It was also proposed 
that the defective targeting, innervation, and synaptogenesis of 
the axons of olfactory sensory neurons to the OB anlage might 
have caused OB dysgenesis in KS patients. Following this 
study, CHH and KS were defined as the partial or complete 
failure of sexual development secondary to the failed embry-
onic establishment of hypothalamic GnRH neurons, which 
causes deficits in the secretion of sex hormones from the ante-
rior pituitary and gonads [4-7].
GENETICS AND GENETIC TESTING
Recently, significant progress in genetic research regarding 
CHH has led to the identification of more than 31 different pu-
tative loci for this disorder, 17 of which are also associated 
with KS [8]. The current list of genes and information on their 
presumed biological activities and inheritance patterns are pro-
vided in Tables 1-3. Although these genes may be implicated in 
the etiology of approximately 50% of CHH/KS cases, the mu-
tations in each of the genes account for less than 10% of such 
cases; furthermore, the majority of the underlying mechanisms 
have yet to be fully characterized [9,10]. 
 CHH/KS may present as either a sporadic or a familial case 
following autosomal dominant, autosomal recessive, or X-
linked recessive modes of inheritance. The variable phenotypes 
among individuals carrying the same mutation within a pedi-
gree, even between monozygotic twins [11], have led to pro-
posals of digenicity or oligogenicity, in which mutations of 
multiple genes synergize to produce a more severe phenotype 
but contribute to the phenotype with a variable penetrance [12]. 
For instance, loss-of-function mutations of semaphorin 7A 
(SEMA3A) have been reported in KS patients, but monoallelic 
mutations of this gene are not sufficient to cause the disease 
phenotype [13]. Thus, mutations of SEMA3A likely contribute 
to the pathogenesis through synergistic effects with mutations 
in other genes. Heparan sulphate 6-O-sulfotransferase 1 
(HS6ST1) mutations account for approximately 2% of CHH 
cases and have been identified in combination with fibroblast 
growth factor receptor 1 (FGFR1) mutations in KS patients 
[14]. Additionally, mutations of prokineticin receptor-2 
(PROKR2) in combination with mutations of anosmin-1 
(ANOS1) [15] and FGFR1 [16] have been identified as well as 
potentially digenic patterns of nasal embryonic luteinizing hor-
mone-releasing hormone factor (NELF)/ANOS1 and NELF/
tachykinin receptor 3 (TACR3) mutations [17]. Patients with 
complex genetic makeups such as these are estimated to com-
prise at least 20% of all cases [10].
 Establishing a phenotype-genotype association can aid phe-
notype-driven priority screening and better inform patient man-
agement and counseling [9]. Recent advancements in DNA se-
quencing technology have led to a wealth of genetic informa-
Table 1. Current List of Genes Associated with Only Kallmann Syndrome      
Gene and protein
 (alternative names) OMIM Known biological activity Reversible Oligogenicity Inheritance
ANOS1 (KAL1) 
 (anosmin-1)
300836 E xtracellular matrix protein modulating FGFR1 
and integrin signaling. Guidance molecule for 
GnRH neuronal migration and survival.
Yes Yes X-linked recessive
FEZF1 
 (FEZ family zinc finger 1)
613301 Z inc finger-containing transcriptional repressor 
regulating the development of forebrain and neo-
cortex. GnRH neuronal migration and survival.
ND ND Autosomal recessive
HESX1 
 ( homeobox gene expressed 
in ES cells 1)
182230 T ranscription repressor for homeodomain-contain-
ing genes. Also involved in combined pituitary 
hormone deficiency and septo-optic dysplasia.
ND ND Autosomal recessive/
 dominant
IL17RD (SEF) 
 (interleukin 17 receptor D)
606807 Negative regulator and interactant of FGFR1. ND Yes Autosomal dominant
SEMA3A 
 (semaphorin-3A)
614897 G uidance molecule for GnRH neuronal migra-
tion and axonal pathfinding.
ND Yes Autosomal dominant
SOX10 
 ( SRY-related HMG-box gene 
10)
602229 R elated to testis-determining transcription factor 
SRY. Regulate neural crest development. Also 
involved in Waardenburg-Shah syndrome.
ND ND Autosomal dominant
OMIM, Online Mendelian Inheritance in Man; FGFR1, fibroblast growth factor receptor 1; GnRH, gonadotrophin-releasing hormone; ND, not deter-
mined; SRY, sex-determining region Y.     
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tion regarding CHH/KS patients. In particular, the recognition 
of oligogenic traits [10,12] has influenced perspectives on the 
genetic testing, diagnosis, and counseling for CHH/KS. For ex-
ample, if an X-linked mode of inheritance is apparent, a muta-
tion of KAL1 (note: following a nomenclature change by the 
Human Genome Organisation, this gene is now designated as 
Table 2. Current List of Genes Associated with Only Congenital Hypogonadotropic Hypogonadism     
Gene and protein
 (alternative names) OMIM Known biological activity Reversible Oligogenicity Inheritance
DMXL2
  (Rabconnectin-3α)
616113 S ynaptic protein involved in stimulation and homeo-
stasis of GnRH neurons and gonadotrophs. Also mu-
tated in polyendocrine-polyneuropathy syndrome.
ND ND Autosomal recessive
GNRH1
 ( gonadotropin-releasing 
hormone 1)
614841 E xclusively expressed by GnRH-releasing neurons. 
Binds to its receptor GnRHR to stimulate HPG axis.
ND ND Autosomal recessive
GNRHR
 ( gonadotropin-releasing 
hormone receptor)
146110 G -protein-coupled 7-transmembrane-domain recep-
tor for GnRH, expressed in the gonadotrophs in 
the pituitary.
Yes Yes Autosomal recessive
KISS1
 (kisspeptin; metastin)
614842 S ecreted by the hypothalamic neurons of arcuate 
and anteroventral periventricular nucleus. Binds to 
its receptor GPR54 to regulate GnRH neurons.
ND ND Autosomal recessive
KISS1R
 ( G-protein-coupled  
receptor 54)
614837 G -protein-coupled receptor for kisspeptin, expressed 
in hypothalamic GnRH neurons.
ND Yes A utosomal recessive/
dominant
LEP 
 (leptin)
614962 A dipocyte-specific hormone regulating food intake, 
energy balance and fat metabolism. Associated 
with obesity.
ND ND Autosomal recessive
LEPR
 (leptin receptor)
614963 S ingle-transmembrane-domain receptor for leptin. 
Preferentially expressed in hypothalamus.
ND ND ND
NR0B1 (DAX1)
 ( nuclear receptor  
subfamily 0, group B)
300200 N egative regulator of retinoic acid receptor. Mutated 
in X-linked congenital adrenal hypoplasia with HH.
ND ND X-linked recessive
OTUD4
 ( OTU domain-containing 
protein 4)
611744 D e-ubiquitinase found to be mutated in Gordon Holmes 
syndrome, a hypogonadism associated with cerebel-
lar ataxia.
ND ND Autosomal recessive
PCSK1
 ( proprotein convertase-1)
162150 R equired for processing of various pre-hormones in-
cluding proopiomelanocortin, proinsulin, and pro-
glucagon.
ND ND ND
PNPLA6
 ( patatin-like phospholi-
pase domain-containing 
protein 6)
603197 C atalyzes the de-esterification of membrane phos-
phatidylcholine. Also mutated in Gordon Holmes 
and Boucher-Neuhauser syndrome.
ND ND Autosomal recessive
RNF216
 (ring finger protein 216)
609948 Z inc finger protein that binds and inhibits TNF and 
NF-κB. Also mutated in Gordon Holmes syndrome.
ND ND Autosomal recessive
TAC3
 ( tachykinin 3; neurokinin B, 
neuromedin-K)
614839 S ecreted in the hypothalamic neurons of arcuate nu-
cleus. Binds to its receptor TACR3 to regulate the 
secretion and homeostasis of GnRH neurons.
Yes Yes Autosomal recessive
TACR3
 ( tachykinin receptor 3; 
neurokinin B receptor, 
neuromedin-K receptor)
614840 G -protein-coupled receptor for TAC3. Expressed in 
hypothalamic GnRH neurons to regulate secretion 
and homeostasis of GnRH.
Yes Yes Autosomal recessive
OMIM, Online Mendelian Inheritance in Man; ND, not determined; HPG, hypothalamic-pituitary-gonadal; GPR54, G-protein-coupled receptor 54; 
DAX1, dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1; HH, hypogonadotropic hypogonadism; TNF, tu-
mor necrosis factor; NF-κB, nuclear factor-κB.          
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ANOS1) is highly likely, especially when unilateral renal agen-
esis (30% to 40% of cases) and bimanual synkinesis (~75% of 
cases) are present [18,19]. Kidney anomalies have not been as-
sociated with FGFR1 mutations, which is consistent with find-
ings showing that the conditional knockout of FGFR1 in the 
mouse ureteric bud did not result in any kidney defects [20]. 
On the other hand, dental agenesis, cleft palate, and/or skeletal 
anomalies accompanied by varying degrees of hypogonadism 
with or without anosmia are indicative of a defective fibroblast 
growth factor (FGF) signaling pathway; thus, screening for 
FGFR1, FGF8, and HS6ST1 is recommended [14,21]. 
 If autosomal recessive inheritance is observed, alternations 
in GNRHR [22], kisspeptin receptor (KISS1R) [23], TACR3 
[24], PROKR2 [25], or FEZ family zinc finger 1 (FEZF1) [26] 
can be suspected. If there are signs of CHARGE syndrome 
(Coloboma, Heart anomalies, Choanal atresia, Retardation of 
growth and/or development, Genital and/or urinary defects, 
and Ear anomalies and/or deafness), the chromodomain heli-
Table 3. Current List of Genes Associated with Both Congenital Hypogonadotropic Hypogonadism and Kallmann Syndrome  
Gene and protein 
 (alternative names) OMIM Known biological activity Reversible Oligogenicity Inheritance
AXL
 ( AXL receptor tyrosine 
kinase)
109135 R eceptor tyrosine kinase containing fibronectin type III 
domain with oncogenic activity. Required for GnRH 
neuron migration.
ND ND ND
CHD7 
 ( chromodomain  
helicase DNA- 
binding protein 7)
612370 T ranscriptional regulator essential for the formation of 
neural crest and the development of forebrain, cranio-
facial bones and heart.
Yes ND Autosomal dominant
FGF8
 ( fibroblast growth  
factor 8)
612702 L igand for FGFR1. Essential morphogen for development 
of forebrain, olfactory GnRH system, skeletal structure 
and heart.
ND Yes Autosomal dominant
FGF17
 ( fibroblast growth  
factor 17)
603725 S imilar to FGF8 as a ligand for FGFR1, but more in pat-
terning the dorsal frontal cortex.
ND Yes ND
FGFR1
 ( fibroblast growth  
factor receptor 1)
147950 R eceptor tyrosine kinase essential for development of 
forebrain, craniofacial niche, and stimulation and se-
cretion of GnRH neurons and gonadotrophs.
Yes Yes Autosomal dominant
HS6ST1
 ( heparan-sulphate 6O-
sulphotransferase 1)
614880 C atalyzes the transfer of sulphate to position 6 of the N-
sulfoglucosamine residue of heparan sulphate, essen-
tial for FGFR1 signaling activity.
Yes Yes Autosomal dominant
NSMF
 ( nasal embryonic  
luteinizing hormone- 
releasing hormone  
factor; NELF)
614838 G uidance molecule for olfactory axon projections re-
quired for the axonophilic migration of GnRH neurons.
Yes Yes ND
PROK2
 (prokineticin 2)
610628 S ecreted by the hypothalamic neurons of suprachiasmatic 
nucleus that regulate circadian clock. Chemoattractant 
for subventricular zone neuronal progenitors. Involved 
in olfactory bulb morphogenesis and the migration and 
stimulation of GnRH neurons.
ND Yes A utosomal recessive/
dominant
PROKR2
 ( prokineticin recep-
tor-2; GPR73L 1)
607123 G -protein-coupled receptor for PROK2. Regulate the 
formation of olfactory bulb, GnRH neuron and repro-
ductive organs.
Yes Yes A utosomal recessive/
dominant
SEMA7A
 (semaphorin 7A)
607961 M embrane-anchored guidance molecule of the semaphorin 
family. Enhances axon outgrowth and interacts with 
integrin receptors.
ND Yes ND
WDR11
 (WD repeat protein 11)
614858 M ember of the WD repeat-containing protein family. 
Expressed in the forebrain and HPG axis.
ND Yes Autosomal dominant
OMIM, Online Mendelian Inheritance in Man; GnRH, gonadotrophin-releasing hormone; ND, not determined; HPG, hypothalamic-pituitary-gonadal.
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case DNA-binding protein 7 (CHD7) gene mutation should be 
considered a priority [27]. Mutations in dosage-sensitive sex 
reversal, adrenal hypoplasia critical region, on chromosome X, 
gene 1 (DAX1) cause CHH associated with adrenal insufficien-
cy [28] and, if congenital deafness is present, then CHD7, 
SRY-related HMG-box gene 10 (SOX10), and/or interleukin 17 
receptor D (IL17RD) can be suspected [21,29]. CHH with obe-
sity may indicate a mutation of leptin (LEP), leptin receptor 
(LEPR), or proprotein convertase-1 (PCSK1) [30,31], whereas 
signs of other syndromic conditions, such as congenital ichthy-
osis [32] or spherocytosis [33], require that a comparative hy-
bridization array or karyotype analysis be performed to detect 
any aberrant chromosomes.
THE EMERGING PICTURE OF 
MOLECULAR PATHOGENESIS 
The developmental failure or misregulation of any one or com-
bination of the genes and the signal pathways that are involved 
in GnRH migration, secretion, and/or activity at any stage will 
result in CHH and KS. For example, FGFR1 plays pleiotropic 
roles in human organogenesis including forebrain, skeleton, 
and neuroendocrine systems. The activity of this receptor is 
regulated not only by the binding of specific FGF ligands but 
also by alternative isoform expressions and other regulatory in-
teractants. There is strong evidence to suggest that defects 
within the FGF signaling pathway underlie the pathogenesis of 
CHH/KS. Mutations in FGF8 (the ligand) and FGFR1 (the re-
ceptor) account for approximately 12% of CHH/KS cases [34]. 
Anosmin-1, a secreted extracellular matrix protein encoded by 
ANOS1, is the first mutated gene to be identified in KS patients 
[35]. Later it was shown that anosmin-1 binds to FGFR1 as a 
co-ligand and acts to fine-tune receptor signaling activity [36]. 
 Heparan sulphate proteoglycans (HSPGs) are cell surface 
co-receptors that are essential for the formation of functional 
FGF/FGFR signaling complexes. The sequence specificity, 
length, and sulphation patterns of heparan sulphate are impor-
tant regulators of receptor activity. Anosmin-1 may play a role 
in the recruitment of specific types of heparan sulphate to the 
FGF8/FGFR1 signaling complex [37]. In addition, mutations 
of HS6ST1, which is an enzyme that regulates the sugar modi-
fication of HSPG, have been identified in CHH patients [14]. 
More recently, mutations in other modulators of the FGFR1 
signaling pathway, including FGF17, IL17RD, dual specificity 
phosphatase 6 (DUSP6), sprout homolog 4 (SPRY4), and fi-
bronectin leucine rich transmembrane protein 3 (FLRT3), have 
been identified [21]; all of these were initially identified as part 
of the so-called FGF8 synexpression group.
 The kisspeptin and tachykinin signaling systems also play 
key roles in the expression and release of GnRH at the time of 
puberty. Subpopulations of neurons that co-express kisspeptin 
and neurokinin-B are located in the arcuate and infundibular 
hypothalamic regions [38], and kisspeptin-producing neurons 
comprise the major afferents to GnRH neurons, which act to 
regulate the tonic feedback control of GnRH and/or gonadotro-
pin secretion as well as the pre-ovulatory surge [39]. However, 
during development, signaling via kisspeptin and its receptor 
GPR54 are not necessarily required for GnRH neuronal migra-
tion per se [40]. Signaling mediated by tachykinin-3 (TAC3), 
which is the precursor of neurokinin-B, and TACR3, which is 
also known as neuromedin-K receptor (NKR), are also impor-
tant for the metabolic regulation of GnRH neurons [38]. 
 Because reproduction requires an adequate energy supply, 
the metabolic status is important for the regulation, stimulation, 
and homeostasis of GnRH neurons and gonadotrophs. In ani-
mal models, the insulin and leptin signaling pathways stimulate 
the reproductive endocrine system and regulate GnRH neuro-
nal function [41]. It has also been shown that kisspeptin-ex-
pressing neurons are sensitive to changes in leptin concentra-
tions and mutations in LEP or LEPR, result in CHH [30]. How-
ever, GnRH and kisspeptin neurons do not express the leptin 
receptor [41]; therefore, the mechanism by which leptin signal-
ing can be detected and transmitted to kisspeptin/GnRH neu-
rons remains unclear.
 Although the molecular mechanisms of many of these puta-
tive genes remain under investigation, they can be divided into 
four categories according to their presumed biological activi-
ties: (1) development of craniofacial and forebrain structures; 
(2) embryonic migration of GnRH neurons; (3) expression and 
secretion of GnRH; and (4) maintenance and homeostasis of 
GnRH neurons and gonadotrophs. These divisions are not mu-
tually exclusive because the associated events are often inter-
dependent and multiple signal pathways cross-talk with one 
another. Ironically, genes that affect human reproduction 
should not be conserved in evolution. Nonetheless, a recent 
study revealed that founder mutations in four known KS/CHH 
genes (GNRH1, TAC3, PROKR2, and GNRHR) are shared by 
multiple unrelated individuals and that one founder allele of 
PROKR2 originated 9,000 years ago, implying there might be 
an advantage associated with this ancient mutation [42].
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DIAGNOSIS AND DIFFERENTIAL 
DIAGNOSIS 
Although it is a relatively rare disorder, CHH/KS is the most 
common form of gonadotrophin deficiency, and it is about five 
times more prevalent in males. The reported frequencies vary 
across studies, ranging from 1 in 8,000 men and 40,000 women 
to 1 in 29,000 men and 130,000 women [43,44]; ORPHA sug-
gests that an average figure of 3.75 in 100,000 people is appro-
priate (www.orpha.net). A diagnosis of KS is often difficult to 
make due to genetic heterogeneities and the broad spectrum of 
phenotypic presentations. Patients with CHH are commonly di-
agnosed in late adolescence or early adulthood. Delayed puber-
ty is classically defined as the absence of virilization and testic-
ular enlargement (testicular volume <4 mL) in conjunction 
with the lack of or low sperm production by age 14 years in 
males and as primary amenorrhea and the absence of breast de-
velopment (Tanner stage I) by age 13 years in females [45]. 
Any signs of eunuchoidal properties along with either anosmia 
or hyposmia should confirm the diagnosis of KS. When either 
a micropenis (5% to 10% of cases) or cryptorchidism (30% of 
cases) is present in infant males in conjunction with a lack of 
neonatal activation of the HPG axis at 3 to 6 months (mini-pu-
berty), an early diagnosis of CHH can be made and then con-
firmed by the hormonal profiling of serum gonadotropins, sex 
steroids, anti-Müllerian hormone (AMH), insulin-like 3 
(INSL3), and inhibin B [46,47]. However, the occurrence of 
severe genital anomalies, such as hypospadias, likely suggests 
the presence of a human chorionic gonadotropin deficiency. 
Patients may also exhibit a variety of non-reproductive anoma-
lies including craniofacial defects, such as cleft lip and/or pal-
ate and hypodontia, and eye defects, such as iris coloboma, 
ptosis, hypertelorism, and oculomotor palsy. Additionally, neu-
rological symptoms, such as bimanual synkinesis, corpus callo-
sum agenesis, and hearing impairments, and/or medical condi-
tions, such as unilateral renal aplasia, may also be present [48]. 
 Hypoplasia or aplasia of the OB and its tracts can be con-
firmed using high-resolution magnetic resonance imaging 
(MRI) but this does not always correlate with the clinical status 
of olfactory function; thus, a diagnosis of anosmia should be 
confirmed by formal smell testing and detailed questioning 
[49]. MRI scans are also useful during the CHH/KS examina-
tion to investigate the possible presence of any tumors or le-
sions in the hypothalamic and pituitary regions and to detect 
any problems in inner ear structures. To assess bone age and 
epiphyseal closure, bone densitometry can be used, whereas 
abdominal and/or pelvic ultrasonography aid in the detection 
of dysmorphisms in the kidney, ovaries, uterus, or testes 
[43,48]. Low serum concentrations of FSH and LH, along with 
low testosterone (<3.7 nmol/L) and estradiol (<0.18 pg/mL) 
levels, are typically a consequence of decreased gonadotropin 
production [47]. Thus, a detailed assessment of anterior pitu-
itary function must be undertaken to rule out other endocrino-
logical conditions involving growth hormone and thyroid or 
adrenal functioning. Hyperprolactinemia may result in acquired 
HH (AHH) and, therefore, normal prolactin levels should also 
be confirmed [50]. 
 Other complex syndromes present with clinical features that 
are similar to those of CHH or KS; these include combined pi-
tuitary hormone deficiency, septo-optic dysplasia, CHARGE 
syndrome, adrenal hypoplasia congenita with HH, Waarden-
burg syndrome, Bardet-Biedl syndrome, Gordon Holmes syn-
drome, Morning Glory syndrome, Hartsfield syndrome, and 
Dandy-Walker syndrome [8]. However, the most challenging 
differential diagnosis is that of constitutional delay of puberty 
and growth (CDPG). In the absence of anosmia, hormone pro-
filing is not always fully informative regarding the confirma-
tion of a diagnosis, although the combination of GnRH and hu-
man chorionic gonadotropin stimulation tests might help [51]. 
Signs that support a diagnosis of CHH include mild pubic and 
axillary hair growth due to the presence of adrenal androgens 
and the lack of a pubertal growth spurt while exhibiting steady 
linear growth. Thus, normal growth but longer arms and legs 
due to prolonged epiphyseal development may be suggestive 
of CHH, whereas individuals who are shorter than normal but 
have a proportional stature and delayed skeletal maturation 
while showing poor growth velocity are more likely to have 
CDPG [50]. Unlike CHH/KS, puberty is spontaneously initiat-
ed and eventually completed in patients with CDGP. Moreover, 
the presence of a micropenis or cryptorchidism, a cleft palate, 
sensorineural deafness, and anosmia are not observed in pa-
tients with CDGP. Nonetheless, no conclusive differential diag-
nostic tests are currently available for the differentiation of 
CHH/KS from CDPG. 
 Patients with CHARGE syndrome have both hypogonadism 
and OB aplasia/hypoplasia and can also share additional traits 
with KS patients, including a cleft lip or palate [52], which 
makes distinguishing this condition from KS extremely diffi-
cult. Potential systematic causes should also be eliminated prior 
to the confirmation of the diagnosis. Celiac disease, eating dis-
orders, excessive exercise, and chronic diseases of the liver and/
or kidney can all lead to AHH. The possibility of hemochroma-
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tosis, pituitary adenomas, and/or brain tumors should also be 
considered [8]. For further details regarding the diagnostic clues 
of CHH/KS, refer to a previously reported case series [48]. 
TREATMENT AND MANAGEMENT 
CHH/KS can be managed more effectively if it is recognized 
during the early stages. The initial assessment of this disease 
typically relies on the physical examination and data obtained 
in primary clinics. Because these patients are often admitted by 
a variety of different clinics (endocrinology, pediatrics, neuro-
surgery, urology, obstetrics, and gynecology), a correct initial 
diagnosis and subsequent referrals are critical for appropriate 
follow-up visits and the systematic management of the disease 
on a long-term basis. Timely treatment to induce puberty can 
be also crucial for sexual, bone, and metabolic health and for 
the minimization of the psychological effects that can be asso-
ciated with CHH/KS. The treatment regimen for CHH is prin-
cipally determined by whether the goal is to develop secondary 
sexual characteristics (virilization or estrogenization) or to in-
duce fertility as well. In most cases, fertility can be induced un-
der specific regimens of testosterone treatment in males and 
estrogen/progesterone treatment in females, but only a few pre-
dictors have been identified [8]. In cases where gonadotrophs 
retain their functional secretory capability, the administration 
of exogenous pulsatile GnRH invariably induces the phasic re-
lease of LH and FSH and can restore puberty and fertility [50]. 
Patients typically require lifelong treatment to maintain normal 
sexual function, yet some patients sustain function of the go-
nads and remain fertile after testosterone withdrawal, which is 
called as “reversible” case [53]. Reversal of CHH may be more 
prevalent than appreciated. According to a retrospective study, 
the estimated lifetime incidence of the spontaneous recovery of 
reproductive function might be as high as 22% [54]. Interest-
ingly, in these reversible cases, there is an enrichment of neuro-
kinin B mutations, and the absence of the OB does not hinder 
the reversal. On the other hand, a subsequent relapse can also 
occur and, therefore, these patients require ongoing monitoring 
for reversal and/or relapse [54]. However, no predictors are 
currently available. 
 Recently, inhibin B, INSL3, AMH, and kisspeptin have 
emerged as potential biomarkers for the diagnosis and treat-
ment of CHH [45-47]. Kisspeptin may also be a potentially 
useful therapeutic target since a male patient reversed his con-
dition after receiving exogenous kisspeptin infusions [45]. Al-
though earlier studies indicate that the neonatal administration 
of gonadotropins could be beneficial [44,50], further investiga-
tion is necessary to confirm its value for fertility outcomes and 
long-term effects. A comparative assessment of gonadotropin 
treatment during adolescence vs. adulthood and the benefits of 
prior treatment with androgens or FSH before pubertal induc-
tion are still under consideration [50]. 
 Many studies have focused on testicular growth and gameto-
genesis in males [46,47], but the rate of pregnancy in females 
with CHH/KS has yet to be sufficiently investigated, although 
this may be partly due to rarity of the disease and the long-term 
follow-up assessments required for gathering such information. 
Patients with cleft lip and/or palate, hearing loss, skeletal de-
fects, or cryptorchidism require surgical and specialist inter-
ventions early in life. CHH/KS patients also have an increased 
risk of metabolic problems such as type 2 diabetes [55]. In fe-
males, low estrogen levels can result in osteopenia/osteoporo-
sis [50] and, thus, bone density should be monitored. Due to 
the congenital nature of the disease, patients with KS who ex-
hibit anosmia or hyposmia do not complain of altered flavor 
perception [49]. However, due to the potential detrimental ef-
fects of KS on quality of life and mental health issues, patients 
with KS should be carefully advised of this disability.
 It is also important to recognize the implications of fertility 
treatment in CHH/KS patients because it leads to the inevitable 
risk of passing on the mutated gene to the next generation; this 
is especially true for genes with an autosomal dominant inheri-
tance that have a 50% chance of transmission. Thus, genetic 
counseling should be provided to enable informed medical and 
personal decisions that rest on a clear understanding of the 
risks involved in conception, which can be even more critical 
in the case of suspected oligogenicity [9,10,50]. Potential com-
plications that may arise during pregnancy in female patients 
with certain anomalies should also be carefully assessed.
 The major challenges associated with the treatment and 
management of CHH/KS include the appropriate timing of the 
treatment and how to promote adherence to treatment, espe-
cially during the transitioning of young adults from pediatric to 
adult care because any gaps can have considerable consequenc-
es. According to the consensus of the European Consortium on 
GnRH biology (COST Action BM1105, http://www.gnrhnet-
work.eu/), a structured transition is preferable. Nonetheless, 
medical treatment provides only some aspects of the overall 
solution as many of the patients are emotionally traumatized, 
particularly by psychosexual issues and low self-esteem [9]. 
Thus, targeted psychosocial interventions, counseling, and peer 
support should aid in the amelioration of some of these issues. 
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CONCLUSIONS
Advancements in next-generation DNA sequencing technology 
hold much hope for more accurate detection and diagnostic 
procedures, personalized genetic counseling and screening, and 
tailored treatments for CHH/KS patients. Furthermore, future 
international multicenter trials that include large patient popu-
lations should aid in the development of an organized consen-
sus for optimal management plans and fertility treatment op-
tions for these patients. Predictions based on genotype-pheno-
type correlations that consider oligogenicity, the identification 
of novel biomarkers, and the development of targeted therapies 
might also become realistic possibilities. Additionally, recent 
findings on the reversibility and oligogenicity of CHH/KS with 
variable phenotypes have challenged the conventional beliefs 
and current dogma associated with congenital defects. CHH/
KS was previously believed to be secondary hypogonadism 
due to the absence of GnRH function [4-7], but many of the 
genes associated with CHH/KS are broadly expressed in the 
HPG axis. Thus, the impact of the mutations may not be limit-
ed to hypothalamic GnRH neurons but may also contribute to 
primary defects in the pituitary or gonads downstream of 
GnRH receptor. Although several genes that ensure proper go-
nadal development have been identified, their links with CHH/
KS has not been established. Additionally, the reversibility of 
this condition underscores the plasticity of the GnRH neuroen-
docrine system and suggests that further research is necessary. 
 Over the years, the distinction between CHH and KS has be-
come even more blurry, in part because the mutations of known 
CHH/KS genes have been identified in other congenital syn-
dromes that include CHH features but are accompanied by dif-
ferent symptoms [8]. The assumption is that it may not be a 
simple “all-or-none” story but rather a complex scenario that 
involves multiple feedback mechanisms. A broad range of as-
sociated phenotypes found in multiple disorders with HH po-
tentially indicate that these issues are caused by overlapping 
signal pathways with different tissue specificities. Therefore, 
the need to redefine these congenital disorders and revise the 
existing perceptions of them is becoming more apparent, and it 
will be necessary to implement stratified medical strategies for 
these patients in the future. 
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